China has tens of thousands of non-bank lenders that are providing increasing amounts of credit to businesses and government outside the mainstream, regulated banking sector, a situation that is stoking systemic risk, Fitch said.
Hot India Companies To Buy Right Now: Amsurg Corp.(AMSG)
AmSurg Corp., through its wholly owned subsidiaries, engages in the development, acquisition, and operation of ambulatory surgery centers in partnership with physicians in the United States. The company?s surgery centers perform colonoscopy and other endoscopy procedures in the area of gastroenterology; cataracts and retinal laser surgery in the area of ophthalmology; and knee and shoulder arthroscopy and carpal tunnel repair in the area of orthopedics. As of December 31, 2010, it owned interest in 204 surgery centers in 33 states and the District of Columbia, including 140 centers performed gastrointestinal endoscopy procedures, 37 centers performed ophthalmology surgery procedures, 19 centers were multiple specialties, and 8 centers performed orthopaedic procedures. AmSurg Corp. markets its surgery centers directly to patients; and referring physicians and third-party payors, such as health maintenance organizations, preferred provider organizations, other managed care o rganizations, and employers. The company was founded in 1992 and is headquartered in Nashville, Tennessee.
Advisors' Opinion:- [By Seth Jayson]
AmSurg (Nasdaq: AMSG ) is expected to report Q1 earnings on April 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AmSurg's revenues will grow 13.6% and EPS will grow 4.0%.
Top 5 Japanese Stocks To Own For 2014: iShares Mortgage Real Estate Capped ETF (REM)
iShares FTSE NAREIT Mortgage REITs Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the FTSE NAREIT Mortgage REITs Index (the Index). The Index measures the performance of the residential and commercial mortgage real estate sector of the United States equity market.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Charles Sizemore]
So, I repeat: use the recent yield spike as an opportunity to scoop up your favorite income investments. If you want to take a modest risk, follow Gundlach�� advice and accumulate mortgage REITs. Your easiest one-stop shop during the market’s taper tantrum would be the iShares Mortgage Real Estate ETF (REM).
- [By Donald van Deventer]
The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday's close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:
- [By Peter F. Way]
An ETF of the mREITs exists, the iShares Mortgage Real Estate Capped (REM). For comparison, its past two-year price history is contrasted with the general market (SPY) and another income alternative the iShares US Preferred Stock ETF (PFF).
Top 5 Japanese Stocks To Own For 2014: InVivo Therapeutics Holdings Corp (NVIV)
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., incorporated on April 2, 2003, is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity, a process where functional recovery can occur through the rerouting of signalling pathways to the spared healthy tissue.
The Company�� biopolymer-based devices are surgically implanted or injected into the lesion created during traumatic injury, or the primary injury. Additional applications of its platform technologies include the treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. Its biocompatible scaffolding device for the treatment of acute spinal cord injury, is regulated as a Class III medical device by the Food and Drug Administration (FDA). The Company's biocompatible hydrogel is used for the local release of methylprednisolone to treat acute spinal cord injuries and the biocompatible polymer scaffolding device seeded with autologous human neural stem cells.
The Company�� porous biopolymer scaffold consists of polylactic-co-glycolic acid (PLGA) and-polylysine. PLGA is a biodegradable and biocompatible polymer, which is used for applications, such as surgical sutures (Dolphin sutures and Ethicon sutures), drug delivery (Lupron Depot and Sandostatin LAR Depot), and tissue engineering (Dermagraft). The PLGA-polylysine biopolymer scaffolding device is biocompatible and biodegradable and degrades naturally inside the body without requiring subsequent removal.
The Company focuses to develop an injectable hydrogel designed to counteract the inflammatory environment that results during a secondary injury from a closed-wound spi! nal cord injury where further cell death occurs. It focuses to counteract the pathophysiology of spinal cord injury by replacing lost cells of the spinal cord and activating endogenous regenerative processes, such as the formation of new synapses and axonal sprouting based on molecules the stem cells produce.
Advisors' Opinion:- [By Bryan Murphy]
I came close to pointing this out yesterday, but didn't pull the trigger. Though delaying didn't cost you or me more than a few cents, I don't want to tarry any longer... Invivo Therapeutics Holdings Corp. (OTCBB:NVIV) is a buy.
Top 5 Japanese Stocks To Own For 2014: Peet's Coffee & Tea Inc.(PEET)
Peet?s Coffee & Tea, Inc. operates as a specialty coffee roaster and marketer of fresh roasted whole bean coffee and tea in the United States. It offers whole bean coffee and related products consisting of products for home brewing, tea, and packaged foods; and beverages and pastries. The company also provides brewing equipment for coffee and tea; paper filters and brewing accessories; and branded and non-branded cups, saucers, travel mugs, and serve ware. Peet?s sells its products through various channels of distribution, including grocery stores; home delivery, office, restaurant, and foodservice accounts; and company-owned and operated stores. As of January 2, 2011, it operated 192 retail stores in California, Colorado, Illinois, Oregon, Massachusetts, and Washington. The company was founded in 1966 and is headquartered in Emeryville, California.
Advisors' Opinion:- [By Chris Hill]
In 2012, the Germany-based�Benckiser Group�spent $1.3B to buy Peet's Coffee & Tea, as well as Caribou Coffee. On Friday, Benckiser announced that it's buying European coffee maker Master Blenders for�around�$10 billion. In the United States, Benckiser is closing 15% of Caribou locations, and�converting 20% of the stores into Peet's (NASDAQ: PEET ) . In this installment of Motley Fool Money, our analysts discuss whether Benckiser's big bet on coffee poses a threat to Starbucks (NASDAQ: SBUX ) .
No comments:
Post a Comment